Laparoscopic right anterior lobe hepatectomy for multiple primary cancers in liver and lungs after conversion therapy：report of 1 case (video attached)

doi:10.3877/cma.j.issn.2095-3232.2025.06.023

Abstract

Key words: Carcinoma, hepatocellular, Pulmonary carcinoma, Multiple primary cancers, Immunotherapy, Targeted therapy, Hepatectomy

Qiaodong Xu, Zhiyan Ma, Gengren Feng. Laparoscopic right anterior lobe hepatectomy for multiple primary cancers in liver and lungs after conversion therapy：report of 1 case (video attached)[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(06): 973-976.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025.06.023

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I06/973

Figures/Tables 2

References 32

[1]	Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase Ⅱ clinical trial[J]. J Immunother Cancer, 2022, 10(4): e004656. DOI: 10.1136/jitc-2022-004656.
[2]	Pu X, Lin G, Xiao M, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase Ⅱ study[J]. EClinicalMedicine, 2024, 67: 102403. DOI: 10.1016/j.eclinm.2023.102403.
[3]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(4): 407-449. DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
[4]	She WH, Cheung TT. Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2024, 30(18): 2479-2481. DOI: 10.3748/wjg.v30.i18.2479.
[5]	Zhang H, Zhang W, Jiang L, et al. Recent advances in systemic therapy for hepatocellular carcinoma[J]. Biomark Res, 2022, 10(1): 3. DOI: 10.1186/s40364-021-00350-4.
[6]	宋枚芳, 马路园, 赵倩, 等. 肝癌分子靶向药物耐药机制及其应对策略研究进展[J]. 中华肝脏病杂志, 2023, 31(10): 1108-1112. DOI: 10.3760/cma.j.cn501113-20220723-00393.
[7]	王汉萍. 肝癌免疫检查点抑制剂治疗相关不良反应及处理[J]. 临床肝胆病杂志, 2022, 38(5): 985-991. DOI: 10.3969/j.issn.1001-5256.2022.05.003.
[8]	李鑫, 高见, 屠红. 免疫检查点抑制剂治疗晚期肝癌的研究进展[J]. 肿瘤, 2021, 41(12): 866-875. DOI: 10.3781/j.issn.1000-7431.2021.2109-0666.
[9]	代欣, 曹博然, 李丹, 等. 肝细胞癌免疫治疗耐药机制研究现状[J]. 肝脏, 2022, 27(10): 1059-1061. DOI: 10.14000/j.cnki.issn.1008-1704.2022.10.021.
[10]	Cheng H, Sun G, Chen H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies[J]. Am J Cancer Res, 2019, 9(8): 1536-1545.
[11]	中华预防医学会肝胆胰疾病预防与控制专业委员会，中国抗癌协会肝癌专业委员会，北京医学会外科学分会肝脏学组.晚期肝细胞癌免疫靶向联合转化序贯外科治疗专家共识(2024版)[J].中华外科杂志， 2024, 62(11): 984-995. DOI: 10.3760/cma.j.cn112139-20240814-00245.
[12]	中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会, 等. 肝细胞癌新辅助及转化治疗中国专家共识(2023版)[J/CD]. 肝癌电子杂志 2023, 10(4): 1-14.
[13]	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.ccr-20-2571.
[14]	Yao Y, Wang Y, Du Y, et al. Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: a prospective, open-label, multicentric study[J]. Int Immunopharmacol, 2023, 125(pt b): 111147. DOI: 10.1016/j.intimp.2023.111147.
[15]	Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma[J]. Ann Surg, 2004, 240(2): 299-305. DOI: 10.1097/01.sla.0000133123.11932.19.
[16]	孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001.
[17]	黄成, 孙惠川. 中晚期肝癌的根治之路——转化治疗[J]. 临床外科杂志, 2021, 29(11): 1008-1011. DOI: 10.3969/j.issn.1005-6483.2021.11.003.
[18]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[19]	Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146. DOI: 10.1016/S0140-6736(23)00961-3.
[20]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7.
[21]	万雪帅, 杜顺达, 毛一雷. 综合治疗时代晚期肝癌治疗的全局观[J]. 腹部外科, 2021, 34(2): 92-97, 100. DOI: 10.3969/j.issn.1003-5591.2021.02.003.
[22]	李自雄, 夏兆珺, 陈超, 等. 中国晚期肝癌患者一线系统性药物治疗有效性和安全性的网络荟萃分析[J]. 临床肿瘤学杂志, 2023, 28(5): 406-414.
[23]	黄傲, 郭德镇, 周俭. 靶向和免疫治疗时代的肝癌转化治疗[J]. 实用肿瘤杂志, 2023, 38(2): 101-104. DOI: 10.13267/j.cnki.syzlzz.2023.017.
[24]	胡智明. 肝癌转化治疗策略[J]. 中华肝胆外科杂志, 2023, 29(6): 401-405. DOI: 10.3760/cma.j.cn113884-20230406-00101.
[25]	杨振云, 陈敏山. 肝癌转化治疗的病例选择标准探讨[J]. 中国癌症防治杂志, 2021, 13(5): 464-468. DOI: 10.3969/j.issn.1674-5671.2021.05.04.
[26]	郭亚明, 朱兴, 戴朝六, 等. 阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的现状[J]. 中华肝胆外科杂志, 2022, 28(10): 789-792. DOI: 10.3760/cma.j.cn113884-20220223-00072.
[27]	Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib[J]. Nature, 2021, 595(7869): 730-734. DOI: 10.1038/s41586-021-03741-7.
[28]	杨帆, 段昌虎, 吴林, 等. 帕博利珠单抗联合乐伐替尼转化治疗后序贯根治性手术在初始不可切除肝癌中的应用效果[J]. 中国药物应用与监测, 2024, 21(4): 385-389. DOI: 10.3969/j.issn.1672-8157.2024.04.017.
[29]	文天夫, 李川, 彭伟, 等. 做细肝细胞癌全程多学科规范化管理[J]. 中华肝胆外科杂志, 2021, 27(9): 641-644. DOI: 10.3760/cma.j.cn113884-20210418-00142.
[30]	姜中豪, 戴朝六. 多学科综合治疗时代肝癌外科新理念[J/OL]. 中华普通外科学文献(电子版), 2020, 14(6): 401-405. DOI: 10.3877/cma.j.issn.1674-0793.2020.06.001.
[31]	毕新宇, 蔡建强. 转化治疗时代的肝脏外科治疗模式[J]. 临床肝胆病杂志, 2024, 40(9): 1721-1724. DOI: 10.12449/JCH240901.
[32]	董晓锋, 杨英豪, 张燕, 等. 原发性肝癌治疗现状及MDT治疗模式的探讨[J]. 肝脏, 2021, 26(3): 262-265. DOI: 10.14000/j.cnki.issn.1008-1704.2021.03.013.

Please choose a citation manager

Content to export

Laparoscopic right anterior lobe hepatectomy for multiple primary cancers in liver and lungs after conversion therapy：report of 1 case (video attached)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 32

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Shidi Zhao, Jiao Yang, Yan Zhou, Yuan Fan, Jin Yang. Challenges and post-progression strategies for CDK4/6 inhibitors in first-line treatment of hormonal receptor positive advanced breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2025, 19(05): 257-266.
[2]	Sijun Wang, Qiong Wang, Keyu Li, Xinpu Yuan, Shuomin Zhang, Rui Ma, Tianyu Xie, Chaojun Zhang. Analysis of clinical efficacy of proximal gastrectomy after neoadjuvant chemotherapy combined with immunotherapy for upper gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 637-641.
[3]	Yuyong Liang, Li Zheng, Jian Yang. Study on the relationship between PDCD4 and disease progression after hepatectomy in patients with primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 666-669.
[4]	Feng Gao, Shaolong Hao, Hao Sun, Wei Han. Research progress of tertiary lymphoid structures in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 570-573.
[5]	Zhicheng Liao, Li Zhu, Zhiyu Zeng. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 27): advanced renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 669-676.
[6]	Zhejing Wu, Jingdong Li. Meta-analysis of safety and efficacy of ICG fluorescence imaging-guided laparoscopic hepatectomy for liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(06): 852-859.
[7]	Yuhan Zhang, Tianqing Wu, Wenqing Gao, Zhikai Zheng, Minrui He, Zhongguo Zhou. Meta-analysis of efficacy and safety of different treatments for unresectable intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(06): 939-947.
[8]	Yue Tang, Jialu Chen, Delong Qin, Zonglong Li, Zhaohui Tang, Zhiwei Quan. Discussion of core and difficult problems of laparoscopic liver resection for recurrent hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 667-672.
[9]	Wenkang Yuan, Chong Zhang, Chao Zhang. Changes in the concept and technical progress of liver surgery [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 673-679.
[10]	Shuirong Lin, Zimin Song, Xi Yu, Shaoqiang Li, Yunpeng Hua, Shunli Shen. Effect of preoperative antiviral therapy on post-hepatectomy liver failure for HBV-associated hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 700-706.
[11]	Yan Zhang, Dingwei Xu, Manqin Hu, Haoyang Huang, Guangna Song, Jie Huang. Predictive value of preoperative inflammatory immune indexes for survival and prognosis of patients with hepatocellular carcinoma after hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 707-715.
[12]	Shanhua Tang, Zhanhong Lai, Haiqing Liu, Xiaozhen Wang, Kai Wang, Jie Zhou. Construction of prediction model for early identification of post-hepatectomy liver failure for liver cancer based on XGBoost [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 725-731.
[13]	Nan Zhao, Mingkai Zhang, Bhargava Divija, Shiguang Zhao, Daming Zhang. Clinical features and strategic advances in the treatment of brain metastases from colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(05): 427-435.
[14]	Chunmao Wang, Ming Han, Zitong Wang. Pathologic complete response after neoadjuvant therapy in limited-stage small cell lung cancer: Report of five cases [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(07): 550-554.
[15]	Yuhan Hou, Fujin Jiang, Sugui Wang. Progress in immunotherapy of bladder cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(06): 471-475.

模态框（Modal）标题

Please choose a citation manager

Content to export

Laparoscopic right anterior lobe hepatectomy for multiple primary cancers in liver and lungs after conversion therapy：report of 1 case (video attached)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 32

Related Articles 15

Recommended Articles

Metrics

Comments